Study of BR113 for people with advanced solid tumors
This study tests an experimental drug, BR113, for people whose cancer has spread and not responded to standard treatments. It may offer a new option for those with advanced solid tumors, and the trial helps determine if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has spread or cannot be removed, and standard treatments have not worked, are not tolerated, or are not available.
- Your tumor must be measurable by imaging, and you must be able to provide a tissue sample from your tumor.
- You should be in fairly good physical condition (able to do light activity) and have adequate organ and bone marrow function.
- You must not have had certain treatments before, including some targeted therapies or the study drug's specific class.
- You must not have certain serious health conditions, such as uncontrolled heart disease, active brain tumors, or severe lung problems.
- fitModel
- fitModel_tags_placeholder
- fitModel_fit_placeholder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This study tests a new drug called SKB118 for advanced solid cancers (any cancer that has spread) that have not responded to standard treatments. The drug is designed to help the immune system fight cancer cells.
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
This trial tests an investigational drug called FL115, given as a shot under the skin, for people with advanced solid tumors who have already tried standard treatments and a type of immunotherapy called a checkpoint inhibitor. The goal is to see if FL115 can help shrink or control the cancer.
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
This trial tests an injection called MHB118C for people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The goal is to see if this new drug can help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.